John Cleland

Oct 25, 2024 | onlinelibrary.wiley.com | Paul Foley |Paul Kalra |John Cleland |Mark C. Petrie

Introduction Iron deficiency is common in patients with heart failure and clinical trials suggest that correction with high-dose intravenous (IV) iron improves symptoms and quality of life and reduces the risk of heart failure hospitalization.1-3 There is a theoretical risk that iron supplements might increase the risk or severity of infection.

Jul 17, 2024 | onlinelibrary.wiley.com | Pierpaolo Pellicori |Joe Cuthbert |Andrew Clark |John Cleland

Invited Editorial Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics? Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study Alexandre Mebazaa, Beth A. Davison, Jan Biegus, Christopher Edwards, Gillian Murtagh, Christos Varounis, Hamlet Hayrapetyan, Hamayak Sisakian, Victor R.

Jul 9, 2024 | onlinelibrary.wiley.com | Arantxa González |John Cleland

Aims Fibrosis is a common feature of many chronic diseases, including heart failure, which can have deleterious effects on cardiac structure and function that are associated with adverse outcomes. By-products of collagen synthesis and degradation, such as carboxy- and amino-terminal pro- or telo-peptides of collagen type I and III (PICP, PINP, PIIINP, and CITP) have been extensively investigated as markers of fibrosis.